Dicerna Pharmaceuticals' GAAP loss for 9M 2021 was $87.852 million, up 15.4% from $76.161 million in the previous year. Revenue increased 23.1% to $151.894 million from $123.351 million a year earlier.
Dicerna Pharmaceuticals' GAAP loss for 9M 2021 was $87.852 million, up 15.4% from $76.161 million in the previous year. Revenue increased 23.1% to $151.894 million from $123.351 million a year earlier. 
sec.gov
English (US) 